CN102038699A - Novel application of paeoniflorin to inflammation resistance - Google Patents
Novel application of paeoniflorin to inflammation resistance Download PDFInfo
- Publication number
- CN102038699A CN102038699A CN2009101808452A CN200910180845A CN102038699A CN 102038699 A CN102038699 A CN 102038699A CN 2009101808452 A CN2009101808452 A CN 2009101808452A CN 200910180845 A CN200910180845 A CN 200910180845A CN 102038699 A CN102038699 A CN 102038699A
- Authority
- CN
- China
- Prior art keywords
- cell
- expression
- peoniflorin
- icam
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to novel application of paeoniflorin to inflammation resistance. Proved by the experiment applied in the invention, the paeoniflorin has the function of remarkably preventing and treating diseases due to inflammatory injury and especially has better effects on diseases due to inflammatory injury, such as arthritis, coronary heart disease, arteriosclerosis and the like.
Description
Technical field
The present invention relates to the application of peoniflorin inflammatory factor, be specifically related to the inhibitory action of peoniflorin in nuclear factor NF-κ B and cell adhesion molecule ICAM-1 expression.
Background technology
NF-κ B is a kind of nuclear factor, and it plays an important role in the adjusting of many immunity and inflammatory reaction by combining with the enhancer sequence specificity and then the expression of the various kinds of cell factor being regulated and control, and is considered to one of co-channel of various inflammatory reactions at present.All have different NF-κ B gene locis in the various histiocyte nuclears, these gene abnormal expression can mediate serious inflammatory damage.
Multiple factors such as TNF-α, LPS can make the NF-kB activation, and it can further stimulate vascular endothelial cell and multiple adhesion factors such as smooth muscle cell secretion ICAM, VCAM after activating.Wherein, ICAM-1 is a kind of derivable cell surface globulin, express under the normal condition and seldom or not express, and activated NF-κ B can impel the expression of ICAM-1 on many cell types significantly to increase with after regulating element combines accordingly.Great expression ICAM-1 is the key that leukocyte recruitment soaks into and cause certain position tissue injury and inflammatory reaction.
Therefore, NF-κ B and downstream controlling gene ICAM-1 thereof can be used as the important function target spot of inflammatory damage therapeutic intervention.The research medicine is to the influence of NF-κ B and adhesion molecule expression in the damaged cell, is of universal significance for the control of the disease that has excessive inflammatory response in the pathophysiological process such as arthritis, coronary heart disease, atherosclerosis etc.
Summary of the invention
The technical problem to be solved in the present invention is a peoniflorin to the therapeutical effect of the inflammatory damage that causes in the inflammatory reaction process, mainly is the adjusting aspect to nuclear factor NF-κ B and cell adhesion molecule ICAM-1.
Described medicine can be by oral, percutaneous or intravenous route administration; Described medicine exists with oral agents, injection and local administration preparation form; Described oral agents comprises capsule, oral liquid, tablet, granule; Described injection comprises injection, freeze-dried powder injection type; Local administration preparation comprises patch.
For addressing the above problem, the invention provides following technical scheme.
The inventor has confirmed that by serial experiment peoniflorin has antiinflammatory action, and especially the inhibitory action to nuclear factor NF-κ B in the inflammatory reaction and cell adhesion molecule ICAM-1 expression is remarkable.
The inventor has adopted experiment in vitro to confirm that peoniflorin can significantly suppress the expression of NF-κ B and ICAM-1 in the vascular endothelial cell that TNF-α handles.The inhibitory action of when its concentration is 0.5mg/ml NF-κ B being expressed is the strongest, suppression ratio average out to 64.5%, and the inhibitory action of during 0.25mg/ml ICAM-1 being expressed is the strongest, suppression ratio average out to 74.5%.
The inventor has adopted experiment in vitro to confirm that peoniflorin can significantly suppress the expression of NF-κ B and ICAM-1 in the vascular smooth muscle cell that TNF-α handles.Inhibitory action to NF-κ B and ICAM-1 expression when concentration is 0.25mg/ml is all the strongest, and suppression ratio on average is respectively 69.5% and 54%.
The inventor has adopted experiment in vitro to confirm that peoniflorin can significantly suppress the expression of NF-κ B and ICAM-1 in the mononuclear phagocyte that LPS handles.Inhibitory action to NF-κ B and ICAM-1 expression when concentration is 0.5mg/ml is all the strongest, and average maximal percentage inhibition is respectively 72.5% and 70.5%.
This experimental result shows expression activation that peoniflorin can be by suppressing NF-κ B in vascular endothelial cell, vascular smooth muscle cell and the mononuclear phagocyte and by the expression of the ICAM-1 of NF-κ B regulation and control, and then reduce the generation of multiple inflammatory factor such as IL-1, IL-6, PDGF, TF, Fas etc. and the gathering and the adhesion of release and inflammatory cell, this effect can be used for the control of the inflammatory damage that inflammatory reaction causes, and especially the control for cardiovascular disease plays an important role.
The specific embodiment
For the ease of understanding the antiphlogistic effects of peoniflorin, the present invention has carried out following pharmacodynamic experiment:
Embodiment 1: the external protective effect to the inductive vascular endothelial cell ECV-304 damage of TNF-α of peoniflorin
With vascular endothelial cell ECV304 (available from Beijing consonance cell resource center) recovery according to a conventional method, add the DMEM culture fluid that contains 10% hyclone in right amount, in 37 ℃, 5%CO
2The conventional cultivation in the constant incubator.Get the digestion of growth conditions good cell then and make single cell suspension, with 5 * 10
4The cell density of individual/ml is inoculated in 2 96 orifice plates, and every hole 200 μ l treat to be used for next step experiment after cell covers with at the bottom of the hole.It is 8 groups that experiment is divided into, and is respectively: cell matched group, TNF-α matched group and peoniflorin variable concentrations group, 5 every group multiple holes.Peoniflorin concentration is established from 0.5mg/ml, becomes 6 concentration with DMEM 2 doubling dilutions successively, is respectively 0.5,0.25,0.125,0.0625,0.0313,0.0156mg/ml.Each administration group cell adds respective concentration peoniflorin effect 2h earlier, and except that the cell matched group, the TNF-α that all the other each groups add 200U/mL respectively stimulates 6h (two 96 well culture plates are handled all identical) afterwards.
After effect finishes, abandon each hole culture fluid and clean cell, every hole adds fixedly 10min of 100 μ l glutaraldehyde solutions; Clean cell and seal 2h with 5% defatted milk powder; The one 96 every hole of orifice plate adds the anti-people NF-of certain dilution rabbit kappa B antibody 50 μ l afterwards, and the every hole of another piece adds certain dilution mouse-anti H-ICAM-1 antibody (being Santa Cruz company product) 50 μ l, and 4 ℃ are spent the night; Clean cell in above-mentioned two 96 orifice plates next day and in the hole of corresponding culture plate, add the goat anti-rabbit igg and the sheep anti-mouse igg (being China fir biotech company in Beijing) of 50 μ l horseradish peroxidase-labeled respectively, hatch 1h for 37 ℃; Cell is cleaned in the back, adds the o-phenylenediamine colour developing, stops the back and reads λ in microplate reader
492nmPlace's light absorption value calculates the suppression ratio of variable concentrations peoniflorin to NF-κ B and ICAM-1 expression, and experiment is carried out two batches.Concrete experimental result sees Table 1,2:
Table 1. peoniflorin is induced the influence that NF-κ B expresses in the ECV-304 cell of damage to TNF-α
Annotate: #: expression is compared with the cell matched group, and difference has significance, p＜0.05;
*: expression is compared with TNF-α matched group, and difference has significance, p＜0.05.
Table 2. peoniflorin is induced the influence that ICAM-1 expresses in the ECV-304 cell of damage to TNF-α
Annotate: #: expression is compared with the cell matched group, and difference has significance, p＜0.05;
*: expression is compared with TNF-α matched group, and difference has significance, p＜0.05.
Data show in the table 1,2, TNF-α matched group is compared with the cell matched group, and NF-κ B and ICAM-1 express and significantly increase, and difference has significance (p＜0.05); After adding the effect of variable concentrations peoniflorin, NF-κ B and ICAM-1 expression significantly are lower than TNF-α group, and difference has significance (p＜0.05); The inhibitory action of when peoniflorin concentration is 0.5mg/ml NF-κ B being expressed is the strongest, suppression ratio average out to 64.5%; The inhibitory action of when its concentration is 0.25mg/ml ICAM-1 being expressed is the strongest, suppression ratio average out to 74.5%.Can draw according to The above results, peoniflorin can significantly suppress the expression activation of NF-κ B in the vascular endothelial cell that TNF-α handles and by the expression of the ICAM-1 of NF-κ B regulation and control, and then suppress generation and release and leukocytic gathering and the adhesion of multiple inflammatory factor such as IL-1, IL-6, PDGF, TF, Fas etc., alleviate its damage to myocardial cell.As seen, peoniflorin can alleviate that various inflammatory factors have the effect of positive important to the damage of myocardial cell in the myocardial ischemia-reperfusion to the control of cardiovascular disease.
Embodiment 2: the external protective effect to the inductive vascular smooth muscle cell VSMC damage of TNF-α of peoniflorin
With vascular smooth muscle cell VSMC (available from Beijing consonance cell resource center) recovery according to a conventional method, add the DMEM culture fluid that contains 10% hyclone in right amount, in 37 ℃, 5%C0
2The conventional cultivation in the constant incubator.Get the digestion of growth conditions good cell then and make single cell suspension, with 5 * 10
4The cell density of individual/ml is inoculated in 96 orifice plates, and every hole 200 μ l treat to be used for next step experiment after cell covers with at the bottom of the hole.It is 8 groups that experiment is divided into, and is respectively: cell matched group, TNF-α matched group and peoniflorin variable concentrations group, 5 every group multiple holes.Peoniflorin concentration is established from 0.5mg/ml, becomes 6 concentration with DMEM 2 doubling dilutions successively, is respectively 0.5,0.25,0.125,0.0625,0.0313,0.0156mg/ml.Each administration group cell adds respective concentration peoniflorin effect 2h earlier, and except that the cell matched group, the TNF-α that all the other each groups add 200U/mL respectively stimulates 6h afterwards.
After effect finishes, abandon each hole culture fluid and clean cell, every hole adds fixedly 10min of 100 μ l glutaraldehyde solutions; Clean cell and seal 2h with 5% defatted milk powder; The one 96 every hole of orifice plate adds the anti-people NF-of certain dilution rabbit kappa B antibody 50 μ l afterwards, and the every hole of another piece adds certain dilution mouse-anti H-ICAM-1 antibody (being Santa Cruz company product) 50 μ l, and 4 ℃ are spent the night; Clean cell in above-mentioned two 96 orifice plates next day and in the hole of corresponding culture plate, add the goat anti-rabbit igg and the sheep anti-mouse igg (being China fir biotech company in Beijing) of 50 μ l horseradish peroxidase-labeled respectively, hatch 1h for 37 ℃; Cell is cleaned in the back, adds the o-phenylenediamine colour developing, stops the back and reads λ in microplate reader
492nmPlace's light absorption value calculates the suppression ratio of variable concentrations peoniflorin to NF-κ B and ICAM-1 expression, and experiment is carried out two batches.Concrete experimental result sees Table 3,4:
Table 3. peoniflorin is induced the influence that NF-κ B expresses in the VSMC cell of damage to TNF-α
Annotate: #: expression is compared with the cell matched group, and difference has significance, p＜0.05;
*: expression is compared with TNF-α matched group, and difference has significance, p＜0.05.
Table 4. peoniflorin is induced the influence that ICAM-1 expresses in the VSMC cell of damage to TNF-α
Annotate: #: expression is compared with the cell matched group, and difference has significance, p＜0.05;
*: expression is compared with TNF-α matched group, and difference has significance, p＜0.05.
Data show in the table 3,4, TNF-α matched group is compared with the cell matched group, and NF-κ B and ICAM-1 express and significantly increase, and difference has significance (p＜0.05); After adding the effect of variable concentrations peoniflorin, NF-κ B and ICAM-1 expression significantly are lower than TNF-α group, and difference has significance (p＜0.05); Inhibitory action to NF-κ B and ICAM-1 expression when peoniflorin concentration is 0.25mg/ml is all the strongest, and suppression ratio on average is respectively 69.5% and 54%.Can draw according to The above results, peoniflorin can significantly suppress the expression activation of NF-κ B in the vascular smooth muscle cell that TNF-α handles and by the expression of the ICAM-1 of NF-κ B regulation and control, and then suppress leukocytic gathering and adhesion, reduce the release of inflammatory factors such as IL-1, IL-6, PDGF, TF, Fas, block the vascular smooth muscle cell hyperplasia of bringing out after it stimulates, the speed of angiostenosis pathological changes and degree when alleviating atherosclerosis have important effect to the control of cardiovascular disease.
Embodiment 3: the external protective effect to the inductive mononuclear phagocyte RAW264-7 damage of LPS of peoniflorin
RAW264-7 cell (the mouse monokaryon macrophage is available from Shanghai cell research institute) adds the DMEM culture fluid that contains 10% hyclone in right amount, in 37 ℃, 5%CO
2The conventional cultivation in the constant incubator.Get the digestion of growth conditions good cell then and make single cell suspension, with 5 * 10
4The cell density of individual/ml is inoculated in 96 orifice plates, and every hole 200 μ l treat to be used for next step experiment after cell covers with at the bottom of the hole.It is 8 groups that experiment is divided into, and is respectively: cell matched group, LPS matched group and peoniflorin variable concentrations group, 5 every group multiple holes.Peoniflorin concentration is established from 0.5mg/ml, becomes 6 concentration with DMEM 2 doubling dilutions successively, is respectively 0.5,0.25,0.125,0.0625,0.0313,0.0156mg/ml.Each administration group cell adds respective concentration peoniflorin effect 2h earlier, and except that the cell matched group, the LPS that all the other each groups add 2 μ g/ml respectively stimulates 8h afterwards.
After effect finishes, abandon each hole culture fluid and clean cell, every hole adds fixedly 10min of 100 μ l glutaraldehyde solutions; Clean cell and seal 2h with 5% defatted milk powder; The one 96 every hole of orifice plate adds the anti-people NF-of certain dilution rabbit kappa B antibody 50 μ l afterwards, and the every hole of another piece adds certain dilution mouse-anti H-ICAM-1 antibody (being Santa Cruz company product) 50 μ l, and 4 ℃ are spent the night; Clean cell in above-mentioned two 96 orifice plates next day and in the hole of corresponding culture plate, add the goat anti-rabbit igg and the sheep anti-mouse igg (being China fir biotech company in Beijing) of 50 μ l horseradish peroxidase-labeled respectively, hatch 1h for 37 ℃; Cell is cleaned in the back, adds the o-phenylenediamine colour developing, stops the back and reads λ in microplate reader
492nmPlace's light absorption value calculates the suppression ratio of variable concentrations peoniflorin to NF-κ B and ICAM-1 expression, and experiment is carried out two batches, and concrete experimental result sees Table 5,6:
Table 5. peoniflorin is induced the influence that NF-κ B expresses in the RAW264-7 cell of damage to LPS
Annotate: #: expression is compared with the cell matched group, and difference has significance, p＜0.05;
*: expression is compared with the LPS matched group, and difference has significance, p＜0.05.
Table 6. peoniflorin is induced the influence that ICAM-1 expresses in the RAW264-7 cell of damage to LPS
Annotate: #: expression is compared with the cell matched group, and difference has significance, p＜0.05;
*: expression is compared with the LPS matched group, and difference has significance, p＜0.05.
Data show in the table 5,6, the LPS matched group is compared with the cell matched group, and NF-κ B and ICAM-1 express and significantly increase, and difference has significance (p＜0.05); After adding the effect of variable concentrations peoniflorin, NF-κ B and ICAM-1 expression significantly are lower than TNF-α group, and difference has significance (p＜0.05); Inhibitory action to NF-κ B and ICAM-1 expression when peoniflorin concentration is 0.5mg/ml is all the strongest, and average maximal percentage inhibition is respectively 72.5% and 70.5%.Can draw according to The above results, peoniflorin can significantly suppress the expression activation of NF-κ B in the mononuclear phagocyte that LPS handles and by the expression of the ICAM-1 of NF-κ B regulation and control, and then the adhesion of inhibition mononuclear cell and endotheliocyte and inside subcutaneous infiltration, the blocking-up mononuclear cell is divided into macrophage, the final formation that reduces foam cell in the Atherosclerosis, delay atherosclerotic generation and development, the control of cardiovascular disease is had the effect of positive important.
The activation of NF-κ B and regulation and control that its downstream target gene ICAM-1 is transcribed play pivotal role in the developing of inflammation, but when the abnormal expression of the two increases, will cause multiple inflammatory damage, comprise rheumatoid arthritis, multiple sclerosis, asthma, coronary heart disease etc., and effectively anti-inflammatory treatment has tangible mitigation to above-mentioned diseases associated with inflammation.By data among the above table 1-6 as can be known, peoniflorin can effectively suppress the expression of nuclear factor NF-κ B and cell adhesion molecule ICAM-1, and it is respectively 64.5%, 69.5%, 72.5% to the average maximal percentage inhibition that NF-κ B in vascular endothelial cell, vascular smooth muscle cell and the mononuclear phagocyte cell expresses; The maximal percentage inhibition meansigma methods that ICAM-1 is expressed is respectively 74.5%, 54%, 70.5%.As seen, peoniflorin can pass through to suppress the expression of NF κ B and ICAM-1, and has certain antiinflammatory action.
Peoniflorin can suppress the expression activation of NF-κ B in vascular endothelial cell, vascular smooth muscle cell and the mononuclear phagocyte and by the expression of the ICAM-1 of NF-κ B regulation and control, and then suppressing the generation of multiple inflammatory factor such as IL-1, IL-6, PDGF, TF, Fas etc. and the gathering and the adhesion of release and inflammatory cell, this effect plays an important role for the control of cardiovascular disease.More than effect can alleviate on the one hand the further damage to damaged myocardium of the multiple inflammatory factor that discharges in the myocardial ischemia-reperfusion process; Can suppress leukocytic gathering and adhesion on the other hand, reduce inflammatory factor stimulated vascular smooth muscle cell hyperplasia, and then the speed and the degree of angiostenosis pathological changes when alleviating atherosclerosis; In addition, can suppress the adhesion of mononuclear cell and endotheliocyte and inside subcutaneous infiltration, and then the blocking-up mononuclear cell is divided into macrophage, reduces the formation of foam cell in the Atherosclerosis, delay atherosclerotic generation and development.As seen, peoniflorin can pass through to suppress the expression of NF-κ B and ICAM-1, and is significant in the control of multiple cardiovascular disease such as atherosclerosis, coronary heart disease, ischemical reperfusion injury, heart failure.
Claims (8)
1. the application of peoniflorin inflammation-inhibiting reaction is characterized in that the conciliation effect to nuclear factor NF-κ B and/or cell adhesion molecule ICAM-1 expression.
2. application according to claim 1 is characterized in that the described inhibitory action that is adjusted to nuclear factor NF-κ B and/or cell adhesion molecule ICAM-1 expression.
3. application according to claim 2 is characterized in that described inhibition for regulating the expression activation of NF-κ B in vascular endothelial cell, vascular smooth muscle cell, the mononuclear phagocyte, and/or by the expression of the ICAM-1 of NF-κ B regulation and control.
4. application according to claim 3 is characterized in that describedly being expressed as one or more generation and the release that reduces in IL-1, IL-6, PDGF, TF, the Fas inflammatory factor, and/or the gathering of inflammatory cell and adherent inflammatory reaction.
5. the application of stating according to claim 4 is characterized in that described being applied as prevents and/or treats the inflammatory damage disease that above-mentioned inflammatory reaction causes.
6. application according to claim 5, the disease that it is characterized in that described inflammatory damage is rheumatoid arthritis, multiple sclerosis, asthma, coronary heart disease, arteriosclerosis.
7. application according to claim 1 is characterized in that described medicine is made up of the peoniflorin and the pharmaceutically acceptable carrier of effective dose, and carrier comprises oral formulations carrier, ejection preparation carrier, local administration preparation carrier.
8. application according to claim 7 is characterized in that described medicine exists with oral agents, injection and local administration preparation form, and oral agents comprises capsule, oral liquid, pill, tablet, granule; Described injection comprises injection, freeze-dried powder injection; Local administration preparation comprises cream, ointment, patch, spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101808452A CN102038699A (en) | 2009-10-19 | 2009-10-19 | Novel application of paeoniflorin to inflammation resistance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101808452A CN102038699A (en) | 2009-10-19 | 2009-10-19 | Novel application of paeoniflorin to inflammation resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102038699A true CN102038699A (en) | 2011-05-04 |
Family
ID=43905463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101808452A Pending CN102038699A (en) | 2009-10-19 | 2009-10-19 | Novel application of paeoniflorin to inflammation resistance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102038699A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705502A (en) * | 2014-01-09 | 2014-04-09 | 江苏省中国科学院植物研究所 | Application of flavonoid compound in treating inflammatory diseases |
| CN105796581A (en) * | 2016-03-13 | 2016-07-27 | 长春中医药大学 | Application of paeoniflorin to preparation of medicine for regulating and controlling cholinergic anti-inflammatory pathway |
| CN108815162A (en) * | 2018-08-24 | 2018-11-16 | 四川省人民医院 | Benzoyl aconine compatibility Paeoniflorin is preparing the purposes in treating rheumatoid arthritis drug |
-
2009
- 2009-10-19 CN CN2009101808452A patent/CN102038699A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705502A (en) * | 2014-01-09 | 2014-04-09 | 江苏省中国科学院植物研究所 | Application of flavonoid compound in treating inflammatory diseases |
| CN105796581A (en) * | 2016-03-13 | 2016-07-27 | 长春中医药大学 | Application of paeoniflorin to preparation of medicine for regulating and controlling cholinergic anti-inflammatory pathway |
| CN108815162A (en) * | 2018-08-24 | 2018-11-16 | 四川省人民医院 | Benzoyl aconine compatibility Paeoniflorin is preparing the purposes in treating rheumatoid arthritis drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69637050T2 (en) | USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA HEMMER | |
| JP6117915B2 (en) | Pharmaceutical composition for preventing or treating STAT3-mediated diseases, comprising an extract of Mizokouju or a fraction thereof as an active ingredient | |
| EA028550B1 (en) | Ghrelin o-acyl transferase inhibitor | |
| RU2013120322A (en) | METHODS FOR TREATING PSORIASIS | |
| WO2021263250A2 (en) | Method of treating severe forms of pulmonary hypertension | |
| CN102038699A (en) | Novel application of paeoniflorin to inflammation resistance | |
| CN111646977B (en) | Compound for target ubiquitination degradation of TGF-beta 1 and preparation method and application thereof | |
| KR102016078B1 (en) | Composition for preventing or treating of cardiovascular disease | |
| US11077137B2 (en) | Method for treating diastolic heart failure by inhibiting galectin-3 | |
| Xiao et al. | Effects of esculentoside A on production of interleukin-1, 2, and prostaglandin E~ 2 | |
| CN110090236B (en) | Pharmaceutical composition and use thereof | |
| Kahan | The potential role of rapamycin in pediatric transplantation as observed from adult studies | |
| KR102456307B1 (en) | Composition for preventing or treating of multiple organ failure related to infection comprising 3'-Sialyllactose, 6'-Sialyllactose or Derivatives Thereof | |
| CN107007821A (en) | Interleukin Ⅲ 8 is preparing the application in preventing and treating obesity and metabolic syndrome product | |
| KR20200082734A (en) | A composition comprising alverine for preventing or treating for inflammatory disease | |
| JP7349362B2 (en) | Compounds, methods for producing compounds, enriched extracts, active fractions of enriched extracts, methods for producing enriched extracts, methods for selecting plant biomass to produce enriched extracts, treating immune disorders Compositions for and their uses | |
| EP4248964A1 (en) | Pharmaceutical composition for treating sepsis, and use thereof | |
| KR102057388B1 (en) | Composition for anti-inflammatory treatment comprising nardosinone-based metabolites | |
| CN107998116B (en) | Application of acetamide in anti-psoriasis medicine | |
| CN107693790B (en) | Combination for the treatment of lung cancer | |
| CN111904961A (en) | Application of lycorine in preparation of T cell immunosuppressant | |
| KR102261367B1 (en) | A composition comprising alverine for preventing or treating for inflammatory disease | |
| CN109806264B (en) | Pharmaceutical composition and application thereof | |
| US20240102016A1 (en) | Application of vegfr gene expression inhibitor in preparing preparation or as preparation for treating psoriasis | |
| JPWO2003011276A1 (en) | NFκB inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110504 |